InsidersTradesSigma
Follow the Dianthus Therapeutics, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €6.2bn. The latest transaction was filed on 10 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: ADAM VENESS. All data is accessible without an account.
Analysts rate Dianthus Therapeutics, Inc. Strong Buy (bullish), based on 13 analysts. Average price target: US$137.62.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
4 of 4 declarations
Dianthus Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for the treatment of autoimmune diseases. It specializes in the research and commercialization of drugs that enhance patients' quality of life.